NEW YORK (GenomeWeb News) – Sequenom said after the close of the market on Monday that its board has authorized a "review of potential strategic alternatives" for its Genetic Analysis segment.

The San Diego-based firm has hired Jefferies as a financial advisor and will evaluate "a full range of potential strategic alternatives" for the Genetic Analysis business. It has not decided to enter into any transaction at this point, and "there can be no assurance that Sequenom will enter into such a transaction in the future," it said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.